The Manufacturers Life Insurance Company Makes New $9.61 Million Investment in Krystal Biotech, Inc. $KRYS

The Manufacturers Life Insurance Company bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 25,867 shares of the company’s stock, valued at approximately $9,614,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. S Squared Technology LLC acquired a new stake in shares of Krystal Biotech during the 2nd quarter valued at approximately $28,821,150. OMERS ADMINISTRATION Corp acquired a new stake in shares of Krystal Biotech in the 2nd quarter worth approximately $1,442,000. Sanctuary Advisors LLC purchased a new position in Krystal Biotech in the 2nd quarter valued at approximately $1,001,000. Biondo Investment Advisors LLC purchased a new position in Krystal Biotech in the 2nd quarter valued at approximately $26,368,000. Finally, Elevation Point Wealth Partners LLC acquired a new position in Krystal Biotech during the second quarter worth $447,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on KRYS. TD Cowen boosted their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. HC Wainwright increased their price objective on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Finally, Evercore restated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Krystal Biotech currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Krystal Biotech Stock Down 1.7%

NASDAQ KRYS opened at $351.46 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The business has a fifty day moving average of $348.64 and a 200-day moving average of $304.16. The stock has a market cap of $10.40 billion, a price-to-earnings ratio of 44.04 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. As a group, analysts anticipate that Krystal Biotech, Inc. will post 7.48 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 51,000 shares of company stock worth $16,278,020. Corporate insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.